Browse by category

New data from Fractyl Health’s Revita-1 and Revita-2 studies presented at Digestive Disease Week 2022 builds on this earlier evidence to...

Two-year durability data from the REVITA-1 clinical study, conducted at centres in Europe and South America, revealed that HbA1c was...

Fractyl Health has announced the publication of an innovative new model of metabolism, the Metabolic Balance Model. The study synthesises...

Fractyl Health (formerly Fractyl Laboratories) has closed a US$100 million Series F financing to support multiple late-stage clinical...

Fractyl Laboratories has announced that the FDA has granted Breakthrough Device Designation for Revita DMR (duodenal mucosal resurfacing)...

Fractyl Laboratories has announced the enrolment of the first patient in a pivotal clinical trial of Revita DMR (duodenal mucosal...

Outcomes form the investigator-initiated INSPIRE clinical trial, conducted in collaboration with Fractyl, have demonstrate that a...